HHS Launches Multi-Agency Initiative to Reclaim U.S. Leadership in Clinical Research
核心洞察
The Department of Health and Human Services announced a coordinated effort across FDA, NIH, CMS, ONC, ARPA-H (搜索), and the HHS Office of Inspector General (搜索) to strengthen America's clinical research enterprise.
China now conducts more early-stage clinical trials than the United States, and Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity in 2025.
FDA estimates that streamlining Phase 1 development and clarifying approval pathways could reduce drug development timelines by 6 to 12 months.
The Department of Health and Human Services, under the leadership of Secretary Robert F. Kennedy Jr., has launched a sweeping multi-agency initiative aimed at restoring America's dominance in clinical research and medical innovation. The coordinated effort, announced today, brings together the FDA, NIH, CMS, the Office of the National Coordinator for Health Information Technology (搜索) (ONC), ARPA-H (搜索), and the HHS Office of Inspector General (搜索) to address what the administration describes as an erosion of U.S. competitiveness in the global pharmaceutical landscape.
The urgency behind this initiative is underscored by stark competitive realities. A recent study found that China now conducts more early-stage clinical trials than the United States. Furthermore, in 2025, Chinese companies accounted for nearly half of global pharmaceutical licensing deal activity. "Those trends should concern every American," Kennedy wrote in an opinion piece announcing the initiative.
The Strategic Importance of Clinical Research
For nearly 80 years, clinical trials have served as the engine of medical progress, transforming scientific discoveries into treatments that save lives. Beyond generating evidence for safety and efficacy, clinical trials attract investment, scientific talent, and the infrastructure that supports future innovation. "When clinical research moves overseas, those advantages often move with it," Kennedy noted.
Early-stage clinical trials hold particular strategic significance because they determine where new technologies are tested, refined, and validated. They influence where companies expand, where expertise develops, and which countries will lead the next generation of medical innovation. The administration argues that clinical research creates high-skilled jobs, gives patients earlier access to innovative therapies, and strengthens a sector that directly affects economic prosperity, public health, and national security.
Agency-Level Actions
At the FDA, Acting Commissioner Kyle Diamantas and career leadership are pursuing several reforms. The agency is clarifying expectations for sponsors, streamlining Phase 1 development, and developing a pilot program to accelerate early-stage clinical trials. The FDA estimates these changes could reduce development timelines by 6 to 12 months. Additionally, the agency has clarified that, in many cases, one high-quality clinical trial supported by confirmatory evidence may provide the basis for approval, potentially reducing the evidentiary burden for drug sponsors.
At the NIH, Director Jay Bhattacharya is strengthening support for informative, well-powered clinical trials while advancing artificial intelligence, human cell-based models, real-world data, and other tools designed to move promising therapies to patients more efficiently. NIH researchers are also applying lessons from pioneering personalized gene-editing therapies and working to streamline cancer clinical trials and improve enrollment.
The Office of the National Coordinator is working to connect more eligible patients with clinical trials through electronic health records and other digital tools integrated into routine care. ARPA-H (搜索) is developing technologies that identify promising therapies earlier, predict safety issues sooner, improve trial design, and reduce development costs. Meanwhile, the HHS Office of Inspector General (搜索) is seeking public input on whether existing regulations create unnecessary obstacles to compensating clinical trial participants while preserving safeguards against fraud and abuse.
A Call for Broader Collaboration
Kennedy emphasized that government cannot achieve the stated objective alone. "Researchers, health systems, academic medical centers, technology companies, contract research organizations and pharmaceutical developers all have a role to play," he wrote. The administration is inviting stakeholders to identify regulations, contracting requirements, or institutional practices that slow research without improving safety.
At the same time, Kennedy affirmed that the administration will protect core principles: "Patients deserve transparency, informed consent and confidence that medical decisions rest on rigorous scientific evidence. We can accelerate clinical research without compromising scientific and ethical integrity."
The overarching goal, as articulated by HHS leadership, is straightforward: make the United States the best place in the world to conduct clinical research and develop new medicines, thereby rebuilding the foundation for the next generation of medical breakthroughs.